Navigation Links
Alzheimer's Therapeutics Reviewed by NeuroPerspective
Date:9/6/2012

CARDIFF, Calif., Sept. 6, 2012 /PRNewswire/ -- NI Research has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. The focus is particularly timely, given the recent release of Phase III results for bapineuzumab and solaneuzumab, which serve as a reminder of how poorly the pharma industry has allocated its resources to date, both in terms of the premature embrace of the amyloid model, and the rush into hugely expensive Phase III programs without obtaining Phase II justification.

This 46-page issue is the largest and most comprehensive issue of NeuroPerspective ever produced, and includes:

1) An overview of the biology of Alzheimer's as it is currently conceptualized, albeit not yet validated.
2) A review of the many therapeutic strategies that have been employed, and that are currently under development.
3) The companies and programs that are in clinical, preclinical, and discovery stage. Over 215 therapeutic programs are covered in this review. They include variations on the secretase theme from Bristol Myers Squibb, EnVivo Pharmaceuticals, and Neurogenetic Pharmaceuticals; innovative approaches to disease progression from Merck/Alectos, Roche/reMYND, and NeuroPhage; and those with clinical data, such as EnVivo, Lundbeck, TauRx, and Prana.  
4) What is and is not clear from the sparse solanezumab results thus far disclosed, which have served as a Rorschach for those looking to have their preconceptions supported. With all due respect to the fever dreams of some Street analysts, these results are not going to be the basis for filing a NDA.
5) A sampling of novel biomarkers in development for AD, aimed at identifying markers for MCI/prodromal AD that will permit early intervention.
6) A spotlight review of AC Immune, one of the leaders in the development of antibodies for both amyloid and tau.
7) The positive results for EnVivo Pharma's EVP-6124, and the potential for alternate mechanistic approaches to effectively address Alzheimer's.

Other topics covered in NP September:
8) Reading between the line regarding Naurex's rapid-acting antidepressant, the most important neuropsychiatric development of the year.
9) 'Elan 1969-2013:' Ramifications of Elan's decision to spin-out Neotope Bioscience.
10) The status of Merck Serono's restructuring and the implications for its CNS programming.
11) News and developments from Cortex Pharmaceuticals, NeuroSearch, and more.

NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective (formerly NeuroInvestment) is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.

A one-year subscription to NeuroPerspective is $2,300. The September issue of NeuroPerspective is available for $400 as a single-issue purchase.

NI Research also publishes NeuroLicensing, the Private CNS Company Review, and has just launched NeuroSynopsis, a monthly four-page summary of the most important highlights from NeuroPerspective. NIR also provides consulting services to the pharma industry.

Further information and online purchasing with immediate delivery are available at http://www.niresearch.com/onlinestore.html


'/>"/>
SOURCE NI Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
2. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
3. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
4. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
5. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
6. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
7. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
8. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
9. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
10. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
11. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell ... treat the disease. Surviving Mesothelioma has just posted an article on the new study. ... based their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces ...
(Date:5/19/2016)... ... May 19, 2016 , ... ... (CRO) has welcomed Abu Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , ... vaccine and translational biomarker discovery studies for preclinical and clinical safety programs. “We’ve ...
(Date:5/18/2016)... -- The Biotech industry continues to face a ... are no opportunities ahead. Today, ActiveWallSt.com has on its list ... ), Seattle Genetics Inc. (NASDAQ: SGEN ), Chiasma ... OPHT ). Sign up now to receive our ... Threshold Pharmaceuticals Inc.,s shares gained 0.68%, closing ...
(Date:5/17/2016)... Haselmeier announces the launch by ... by EMA, the European Medicines Agency. Originally launched in ... the new pen version includes enhancements to further improve ... to patients during use. Its enhanced design ... handle with a larger display window that improves the ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/18/2016)... , March 18, 2016 --> ... of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and ... security companies in the border security market and the continuing ... and Europe has led visiongain to ... improved success. --> defence & security companies ...
Breaking Biology News(10 mins):